The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. Photo courtesy of Rice

As the academic year officially kicks off, professors have started moving in and Rice University has opened its largest core campus research facility, The Ralph S. O’Connor Building for Engineering and Science.

The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. The university aims for the space to foster collaboration and innovation between the disciplines.

"To me it really speaks to where Rice wants to go as we grow our research endeavors on campus," Michael Wong, Chair of the Department of Chemical and Biomolecular Engineering, whose lab is located in the new facility, said in a video from Rice. "It has to be a mix of engineering and science to do great things. We don’t want to do good things, we want to do great things. And this building will allow us to do that."

At $152 million, the state-of-the-art facility features five floors of labs, classrooms and seminar rooms. Common spaces and a cafe encourage communication between departments, and the top level is home to a reception suite and outdoor terrace with views of the Houston skyline.

It replaces 1940s-era Abercrombie Engineering Laboratory on campus, which was demolished in 2021 to make way for the new facilities. The iconic sculpture "Energy" by Rice alumnus William McVey that was part of the original building was preserved with plans to incorporate it into the new space.

The new building will be dedicated to its namesake Ralph O'Connor on Sept. 14 in Rice's engineering quad at 3 p.m. O'Connor, a Johns Hopkins University grad, became a fan Rice when he moved to Houston to work in the energy industry in the 1950s.

The former president and CEO of the Highland Oil Company and founder of Ralph S. O’Connor & Associates left the university $57 million from his estate after he died in 2018. The gift was the largest donation from an estate in Rice's history and brought his donations to the university, including those to many buildings on campus and endowments and scholarships, to a total of $85 million.

“How fitting that this building will be named after Ralph O’Connor,” Rice President Reginald DesRoches said in a statement last summer. “He was a man who always looked to the future, and the future is what this new engineering and science building is all about. Discoveries made within those walls could transform the world. Anybody who knew Ralph O’Connor knows he would have loved that.”

The dedication event will be open to the public. It will feature remarks from DesRoches, as well as Rice Provost Amy Dittmar, Dean of the Wiess School of Natural Sciences Thomas Killian, Chair of the Rice Board of Trustees Robert Ladd and Dean of the George R. Brown School of Engineering Luay Nakhleh. A reception and tours of the new building will follow.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."